Drug Delivery to the Brain (eBook)

Margareta Hammarlund-Udenaes (PhD) is a Professor in Pharmacokinetics and Pharmacodynamics (PKPD) at Uppsala University and the Head of the Translational PKPD Group. Her research is focused at studying pharmacokinetic aspects of BBB transport of drugs in relation to CNS effects, which has led to the development of new concepts and methods within the BBB transport area, focusing on unbound drug relationships. Dr. Hammarlund-Udenaes is an Associate Editor of Pharmaceutical Research and a member of the Editorial Advisory Board of Journal of Pharmaceutical Sciences and Fluids and Barriers of the CNS. She became an American Association of Pharmaceutical Scientists’ Fellow in 2005. She is a frequent lecturer at conferences and in drug industry. Her company gives courses and advice in PKPD and BBB transport issues. She co-founded and has co-chaired several of the International Symposia on Microdialysis, and she is the Chair of the ‘Barriers of the CNS’ Gordon Conference in 2014.Elizabeth C.M. de Lange (PhD) is Head of the Target Site Equilibration Group at the Division of Pharmacology of the Leiden Academic Center for Drug Research (LACDR). Her research program focuses on the development of generally applicable predictive PKPD models on CNS drugs using advanced in vivo animal models and mathematical modeling techniques, with a number of recent successes. She is an Editorial Board member of the journal Fluids and Barriers of the CNS, and an Editorial Advisory Board member of the Journal of Pharmaceutical Sciences and of Pharmaceutical Research. She has been the cofounder and (co-)Chair at the 1st, 2nd and 5th International Symposia on Microdialysis, and has been the Chair of the 9th International Conference on Cerebral Vascular Biology (2011). Among many other functions within the American Association of Pharmaceutical Scientists, she is the 2014 Chair of the Annual Meeting Programming Committee. With her company “In Focus” (www.infocus-ecmdelange.nl) she provides courses, training and advice on microdialysis, pharmacokinetics, BBB transport, intra-brain distribution and PKPD relationships.Robert G. Thorne (PhD) is an Assistant Professor in Pharmaceutical Sciences at the University of Wisconsin-Madison School of Pharmacy and also serves as a Trainer in the Neuroscience, Cellular & Molecular Pathology, and Clinical Neuroengineering Training Programs at the University of Wisconsin-Madison. Dr. Thorne was previously a research scientist and Faculty member in the Department of Physiology & Neuroscience at the New York University School of Medicine. His background includes a Ph.D. in Pharmaceutics (University of Minnesota) and a B.S. in chemical engineering (University of Washington). His research focuses on diffusive and convective transport within the CNS and the development, refinement and optimization of strategies for delivering biologics into the brain. He is a frequent invited speaker on topics related to CNS drug delivery for organizations within academia, foundations, and the biotechnology and pharmaceutical industry. Dr. Thorne is a founder and Council / Steering Committee member of the International Brain Barriers Society (http://www.ibbsoc.org/) as well as the 2016 Chair-elect for the ‘Barriers of the CNS’ Gordon Research Conference. 

I.  PHYSIOLOGY AND BASIC PRINCIPLES FOR DRUG HANDLING BY THE BRAIN1.      Anatomy and physiology of the blood-brain barriersN Joan Abbott2.      Recent Progress in Blood-Brain Barrier and Blood-CSF Barrier Transport Research: Pharmaceutical Relevance for Drug Delivery to the BrainMasanori Tachikawa, Yasuo Uchida, Sumio Ohtsuki and Tetsuya Terasaki3.      Blood-Brain Barrier (BBB) Pharmacoproteomics: A New Research Field Opened up by Quantitative Targeted Absolute Proteomics (QTAP)Yasuo Uchida, Masanori Tachikawa, Sumio Ohtsuki And Tetsuya Terasaki4.      Drug Metabolism at the Blood-Brain and Blood-CSF BarriersXavier Declèves, Nathalie Strazielle, Jean-Michel Scherrmann and Jean-François Ghersi-EgeaII. PHARMACOKINETIC CONCEPTS AND METHODS FOR STUDYING DRUG DELIVERY ACROSS THE BLOOD-BRAIN BARRIER5.      Pharmacokinetic Concepts in Brain Drug DeliveryMargareta Hammarlund-Udenaes6.      In vitro models of blood-brain barriersN Joan Abbott, Diana EM Dolman, Siti R Yusof and Andreas Reichel7.      In situ and in vivo animal modelsQuentin Smith and Ramakrishna Samala8.      Principles of PET and its Role in Understanding Drug Delivery to the BrainStina Syvänen and Roger N. Gunn9.      PKPD Aspects of Brain Drug Delivery in a Translational PerspectiveElizabeth C.M. de LangeIII.  INDUSTRIAL APPROACHES FOR INVESTIGATION OF POTENTIAL CENTRAL NERVOUS SYSTEM DRUGS10.  Drug Discovery Methods for Studying Brain Drug Delivery and DistributionIrena Loryan and Margareta Hammarlund-Udenaes11.  Prediction of Drug Exposure in the Brain from the Chemical StructureMarkus Fridén12.  Integrated Approach to Optimizing CNS Penetration in Drug Discovery: From the old to the new Paradigm and Assessment of Drug-Transporter InteractionsAndreas Reichel13.  Pharmacoeconomic Considerations in CNS Drug DevelopmentDavid GrayIV.  STRATEGIES FOR IMPROVED CENTRAL NERVOUS SYSTEM DRUG DELIVERY14.  Intranasal Drug Delivery to the BrainJeffrey J. Lochhead and Robert G. Thorne15.  Blood-To-Brain Drug Delivery using NanocarriersPieter J. Gaillard, Corine C. Visser, Marco de Boer, Chantal C.M. Appeldoorn and Jaap Rip16.  Development of new Protein Vectors for the Physiologic Delivery of Large Therapeutic Compounds to the CNSReinhard Gabathuler17.  CNS Gene Therapy Utilizing Intravenously Administered Viral VectorsAdam K. Bevan and Brian K. Kaspar18.  Neurosurgical Approaches: Drug Infusion Directly into the Parenchyma or Cerebrospinal FluidKrystof Bankiewicz19.  Osmotic Opening of the BBB for Drug Treatment of Brain Tumors (Focus on Methodological Issues)David Fortin20.  Emerging Engineering Technologies for Opening the BBBElisa E. KonofagouV.  BRAIN DRUG DELIVERY IN DISEASE CONDITIONS21.  Disease Influence on BBB Transport in Inflammatory DisordersGeert Schenk, Gijs Kooij, Arie Reijerkerk and Helga de Vries22.  Disease Influence on BBB Transport in Neurodegenerative DisordersElizabeth C.M. de Lange23.  Drug Delivery in the Context of Stroke and Brain TraumaRichard F. Keep, Jianming Xiang, Ningna Zhou and Anuska V. Andjelkovic24.  Which Drug or Drug Delivery Method can change Clinical Practice for Brain Tumor Therapy?Tali SiegalAppending – Primer on Central Nervous System Structure / Function and the Vasculature, Ventricular System and Fluids of the Brain.  Robert Thorne